Cynosure Group’s Medtronic MDT Stock Holding History

Cynosure Group’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,512	Closed	-$225K	–	39
2022 Q2	$225K	Buy	+2,512	New	+$255K	0.22%	42

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Cynosure Group's MDT Position: Q3 2022 in Review

Cynosure Group sold out of Medtronic (MDT) in Q3 2022, closing a stake of 2,512 shares — an estimated $225K sold.

Cynosure Group first reported a position in MDT in Q2 2022 and held it in 1 quarter. The position peaked at $225K in Q2 2022. 1,932 funds tracked by Wall St. Rank hold MDT as of Q3 2022.

Cynosure Group reported no remaining Medtronic position as of Q3 2022 after selling out during the quarter.
Cynosure Group sold 2,512 Medtronic shares in Q3 2022, an estimated $225K.
Cynosure Group first reported a position in Medtronic in Q2 2022 and held it in 1 quarter.
Cynosure Group's Medtronic position peaked at $225K in Q2 2022.
1,932 funds tracked by Wall St. Rank held Medtronic as of Q3 2022.

Based on Cynosure Group's 13F filing for Q3 2022, filed 14 Nov 2022.